A low-cost COVID-19 vaccine developed by researchers at Stanford Medicine

• 全文链接
• 请求原文

作   者：

Swapna Mukherjee; 

作者机构：

Kolkata-700084;  Department of Microbiology;  Dinabandhu Andrews College; 

期刊名称：

Science & culture

i s s n：

0036-8156

年卷期：

2023 年 89 卷 5/6 期

页   码：

208-209

页   码：

摘   要：

In a study led by Stanford Medicine Researchers (published in Nature Communications 14: 2149, H^April, 2023), a low-cost protein-based COVID-19 vaccine that does not require refrigeration, provided immunity in rhesus monkeys for one year. Though the rapid development of COVID-19 vaccines has been a scientific triumph, the need remains for a globally available vaccine that provides longer-lasting immunity against present and future SARS-CoV-2 variants of concern (VOCs). The new vaccine, called Delta-C70-Ferritin-HexaPro ((DCFHP-alum), a ferritin-based, protein-nanoparticle vaccine, formulated with aluminum hydroxide (alum) as the sole adjuvant, stimulates a stronger immune response against known and new variants. DCFHP-alum can be distributed at low cost because it can be produced in large quantities. Adjuvant alum is inexpensive and, safe for infants. Researchers hope,unlike the bivalent Pfizer/ BioNTech and Moderna mRNA vaccines, DCFHP-alum, can remain unrefrigerated for up to two weeks and will help alleviate the need for boosters while improving herd immunity around the world. Although the vaccine yet to go through human trials, it could be an alternative to the mRNA vaccines widely used for COVID-19.